Volta Medical's AI-Guided Cardiac Ablation Shows Promising Results

Volta Medical has announced the results of its landmark TAILORED-AF clinical trial, demonstrating the efficacy of an AI-guided cardiac ablation procedure combined with pulmonary vein isolation (PVI) in treating persistent atrial fibrillation (AF). The trial, published in Nature Medicine, reveals superior outcomes compared to the conventional PVI-only approach.

The randomized controlled trial involved 370 patients across Europe and the US. Results indicated that 88% of patients in the AI-guided cohort experienced freedom from AF after 12 months, compared to 70% in the PVI-only cohort. The study underscores the effectiveness of Volta's AF-Xplorer™ in identifying abnormal electrograms.

According to CEO Théophile Mohr-Durdez, this trial marks a milestone in interventional cardiology, showcasing AI's potential to enhance cardiovascular treatments. Professor Isabel Deisenhofer emphasized the trial's significance for addressing an underserved patient group.